secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001171843-23-005102
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus reports Q2 net loss $6.5M, soquelitinib shows 3 CR/3 PR in TCL; plans FDA meeting
--------------------------------------------------------------------------------

- Soquelitinib Phase 1/1b: 3 complete, 3 partial responses in 20 evaluable TCL patients.
- ALC >900/mL: 6/14 objective responses; 0/6 below 900. FDA meeting for Phase 3 in Q3.
- Cash $37.0M as of June 30, 2023; projected $28-30M year-end, funding into H2 2024.
- Q2 R&D expense $4.0M (down from $4.9M); net loss $6.5M vs $8.4M in Q2 2022.
- Ciforadenant Phase 1b/2 in RCC initial data expected year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323005102/0001171843-23-005102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323005102/f8k_080823.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-005102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer